Dr. John Carr is a pharmacist who is specialized in Critical Care in Savannah, Georgia. Patients can reach him at 5353 Reynolds St, Savannah or contact him on 912-819-8774. Active license number of Dr. John Carr is RPH029907 for Critical Care in Georgia. Dr. John Carr is a licensed pharmacist who has demonstrated specialized knowledge and skill in the delivery of patient care services by pharmacists, as integral members of interprofessional teams, working to ensure the safe and effective use of medications in critically ill patients.
Complete Profile:
Dr. John Carr speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Dr. John Carr
Specialization:
Critical Care
Credentials:
PHARMD
Gender:
Male
Location:
5353 Reynolds St, Savannah, Georgia, 31405-6015
Phone:
912-819-8774
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Dr. John Carr are as mentioned below.
NPI Number:
1417742602
NPI Enumeration Date:
10 Apr, 2025
NPI Last Update On:
10 Apr, 2025
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Dr. John Carr are as mentioned below.
Specialization
License Number
State
Status
Critical Care
RPH029907
Georgia
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
5 Barrington Cir, Savannah, Georgia
Zip:
31419-9530
Phone Number:
--
Fax Number:
--
Patients can reach Dr. John Carr at 5353 Reynolds St, Savannah, Georgia or can call on phone at 912-819-8774.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 13 October, 2025.